Tumor-associated antigens in brain tumor initiating cell lysate (BTIC lysate TAAs)

Tumor-associated antigens in brain tumor initiating cell (BTIC) lysate represent a complex mixture of proteins derived from a subpopulation of cancer cells known as glioblastoma stem cells (GSCs). These cells are characterized by their ability to self-renew, differentiate into multiple lineages, and resist conventional chemotherapy and radiation, often leading to tumor recurrence. By using a whole-cell lysate rather than a single purified protein, therapeutic strategies aim to present the immune system with a diverse array of targets, including both known and unidentified antigens specific to the stem-like population of the tumor. This approach is primarily utilized in the development of autologous dendritic cell vaccines, such as ICT-121, where a patient's own immune cells are 'trained' ex vivo to recognize the unique molecular signature of their specific cancer's initiating cells. The goal of targeting these antigens is to eliminate the reservoir of cells responsible for tumor regrowth and treatment resistance in aggressive brain cancers like glioblastoma.

Other names

Glioblastoma stem cell lysateGSC lysateBrain tumor initiating cell-derived antigensBTIC-derived TAAs

Active immunotherapy via dendritic cell loading; the lysate provides a broad spectrum of tumor-associated antigens to dendritic cells, which then present these antigens to T-cells to induce a polyclonal cytotoxic T-lymphocyte response against brain tumor initiating cells.